世界の医薬品受託開発・製造市場予測(~2025年):医薬品別(生物製剤、医薬品有効成分)錠剤別(非経口、経口液剤、半固形物)、エンドユーザー別(大型医薬品、小型医薬品、ジェネリック医薬品、CRO)

◆英語タイトル:Pharmaceutical Contract Development and Manufacturing Market (Pharmaceutical, Biologics, Active Pharma ingredients, tablet, Parenteral, Oral Liquid, Semi-Solids), End User (Big Pharma, Small Pharma, Generic Pharma,CRO)-Global Forecast to 2025
◆商品コード:PH7263
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2021年3月10日
◆ページ数:192
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥564,300見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥758,100見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥929,100見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

マーケッツアンドマーケッツ社は世界の医薬品受託開発・製造市場規模が2020年1,007億ドルから2025年1,461億ドルまで、年平均7.7%成長すると予想しています。本市場調査資料では、医薬品受託開発・製造の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、サービス別(医薬品製造サービス、医薬品開発サービス、生物製剤製造サービス)分析、エンドユーザー別(大手製薬会社、中小規模製薬会社、ジェネリック製薬会社、その他)分析、地域別分析、競争状況、企業情報などを掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界の医薬品受託開発・製造市場規模:サービス別(医薬品製造サービス、医薬品開発サービス、生物製剤製造サービス)
・世界の医薬品受託開発・製造市場規模:エンドユーザー別(大手製薬会社、中小規模製薬会社、ジェネリック製薬会社、その他)
・世界の医薬品受託開発・製造市場規模:地域別
・競争状況
・企業情報
【レポートの概要】

“The global pharmaceutical contract development and manufacturing market is projected to reach USD 146.1 billion by 2025 from USD 100.7 billion in 2020, at a CAGR of 7.7% during the forecast period.”
Market growth is driven mainly by factors such as rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs. The increasing demand for biological therapies, growing focus on specialty medicines, growth in the nuclear medicines sector, and advancements in cell and gene therapies are also expected to offer market growth opportunities in the coming years.
“The small and medium-sized pharmaceutical companies segment accounted for the highest growth rate in the pharmaceutical contract development and manufacturing market, byend user, during the forecast period.”
The pharmaceutical contract development and manufacturing market is segmented intobig pharmaceutical companies, small & medium-sized pharmaceutical companies, generic pharmaceutical companies, and other end users.The small and medium-sized pharmaceutical companies segment accounted for the highest growth rate in the pharmaceutical contract development and manufacturing market in 2020. This segment’s high growth can be attributed to the increasing number of emerging pharmaceutical companies that lack the in-house capabilities to manufacture and develop complex formulations and drug products.

“Biologics manufacturing services segment accounted for the highest CAGR.”
Based on service, the pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing, biologics manufacturing, and drug development services. In 2020, the biologics manufacturing servicessegment accounted for the highest growth rate. The major factor driving the growth of this segment is the growing demand for vaccines and biosimilars.
“Asia Pacific: The fastest-growing countryin thepharmaceutical contract development and manufacturing market”
Thepharmaceutical contract development and manufacturing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is projected to register the highest CAGR during the forecast period. This growth can be attributed to factors such as growth in the manufacturing sector, favorable government regulations, growing strategic expansions from leading companies, increasing emphasis on off-patent drugs, and the presence of a highly skilled workforce.

The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 80%and Demand Side 20%
• By Designation: C-level – 25%, D-level – 20%, and Others – 55%
• By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%

Lists of Companies Profiled in the Report:
• Thermo Fisher Scientific Inc. (US)
• Catalent, Inc. (US)
• Lonza Group Ltd. (Switzerland)
• Recipharm AB (Sweden)
• Siegfried Holding AG (Switzerland)
• WuXiAppTec (China)
• Samsung Biologics (South Korea)
• Boehringer Ingelheim International GmbH (Germany)
• Piramal Pharma Solutions (India)
• Vetter Pharma International GmbH (Germany)
• FAMAR Health Care Services (France)
• AbbVie Inc. (US)
• Aenova Group (Germany)
• Almac Group (UK)
• Evonik Industries AG (Germany)
• Cambrex Corporation (US)
• CordenPharma International (Germany)
• Albany Molecular Research Inc. (AMRI) (US)
• FUJIFILM Corporation (Japan)
• BioVectra (Canada)

Research Coverage:
This report provides a detailed picture of thepharmaceutical contract development and manufacturing market. It aims at estimating the size and future growth potential of the market across different segments, such as the service, end user, and region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall pharmaceutical contract development and manufacturing marketand its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

【レポートの目次】

1 INTRODUCTION 25
1.1 OBJECTIVES OF THE STUDY 25
1.2 MARKET DEFINITION 25
1.2.1 INCLUSIONS & EXCLUSIONS 26
1.3 MARKET SCOPE 26
1.3.1 MARKETS COVERED 26
1.3.2 YEARS CONSIDERED FOR THE STUDY 27
1.4 CURRENCY 27
1.5 LIMITATIONS 27
1.6 STAKEHOLDERS 27
1.7 SUMMARY OF CHANGES 28
2 RESEARCH METHODOLOGY 29
2.1 RESEARCH APPROACH 29
2.1.1 SECONDARY DATA 29
2.1.2 PRIMARY DATA 30
FIGURE 1 BREAKDOWN OF PRIMARIES: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 30
2.1.3 MARKET DATA ESTIMATION & TRIANGULATION 31
FIGURE 2 DATA TRIANGULATION METHODOLOGY 31
2.2 MARKET ESTIMATION METHODOLOGY 32
2.2.1 MARKET SIZE ESTIMATION APPROACH 32
FIGURE 3 COMPANY REVENUE ANALYSIS-BASED ESTIMATION 32
FIGURE 4 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SIZE (USD BILLION): FINAL MARKET SIZE 32
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 33
FIGURE 5 FINAL CAGR PROJECTIONS (2020−2025) 33
2.4 INSIGHTS FROM PRIMARIES 34
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS 34
2.5 RESEARCH ASSUMPTIONS 34
3 EXECUTIVE SUMMARY 35
FIGURE 7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SHARE, BY SERVICE, 2019 35
FIGURE 8 BIOLOGICS MANUFACTURING SERVICES MARKET SHARE, BY TYPE, 2019 36
FIGURE 9 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2020 VS. 2025 (USD BILLION) 36
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 37
4 PREMIUM INSIGHTS 39
4.1 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET OVERVIEW 39
FIGURE 11 GROWING DEMAND FOR GENERICS IS ONE OF THE KEY FACTORS DRIVING MARKET GROWTH 39
4.2 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 40
FIGURE 12 PHARMACEUTICAL MANUFACTURING SERVICES TO COMMAND THE LARGEST SHARE OF THE EUROPEAN PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 40
4.3 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET,
BY END USER 41
FIGURE 13 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD 41
4.4 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 42
FIGURE 14 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATES BETWEEN 2020 & 2025 42
5 MARKET OVERVIEW 43
5.1 INTRODUCTION 43
5.2 MARKET DYNAMICS 43
FIGURE 15 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DRIVERS, OPPORTUNITIES, CHALLENGES, AND TRENDS 43
5.2.1 DRIVERS 44
5.2.1.1 Patent expiry and increasing demand for generic drugs 44
5.2.1.2 Increasing investments in pharmaceutical R&D 44
FIGURE 16 NUMBER OF PHARMA COMPANIES WITH ACTIVE DRUG PIPELINE PROJECTS (2010–2020) 44
FIGURE 17 GLOBAL R&D SPENDING (2016–2020) 45
5.2.1.3 Investments in advanced manufacturing technologies by CDMOs 45
5.2.2 OPPORTUNITIES 46
5.2.2.1 Increasing demand for biological therapies 46
5.2.2.2 Growth in the nuclear medicine sector 47
5.2.2.3 Growing demand for cell and gene therapies 47
5.2.3 CHALLENGES 47
5.2.3.1 Introduction of serialization 47
5.2.4 TRENDS 48
5.2.4.1 Expansion in emerging countries 48
5.2.4.2 CDMO industry consolidation 48
TABLE 1 LIST OF ACQUISITIONS 49
5.3 VALUE CHAIN ANALYSIS 49
FIGURE 18 VALUE CHAIN ANALYSIS OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 50

5.4 ECOSYSTEM MARKET MAP 51
FIGURE 19 ECOSYSTEM OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 51
5.5 SUPPLY CHAIN 51
5.6 IMPACT OF THE COVID-19 PANDEMIC ON THE GROWTH OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 52
TABLE 2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 53
5.6.1 IMPACT ON THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 54
FIGURE 20 PRE-COVID VS. POST-COVID-19 SCENARIO, 2019–2021 54
5.7 REGULATORY ASSESSMENT 54
5.7.1 INTRODUCTION 54
5.8 PORTER’S FIVE FORCES ANALYSIS 57
5.8.1 THREAT OF NEW ENTRANTS 57
5.8.2 THREAT OF SUBSTITUTES 57
5.8.3 BARGAINING POWER OF SUPPLIERS 58
5.8.4 BARGAINING POWER OF BUYERS 58
5.8.5 DEGREE OF COMPETITION 58
6 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE 59
6.1 INTRODUCTION 60
TABLE 3 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION) 60
6.2 PHARMACEUTICAL MANUFACTURING SERVICES 60
TABLE 4 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION) 61
TABLE 5 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 61
6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES 62
6.2.1.1 Need to cut costs and ensure focus on core areas leads companies to outsource API manufacturing 62
TABLE 6 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 63
6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES 63
TABLE 7 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 64
TABLE 8 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 64
6.2.2.1 Parenteral/injectable manufacturing services 65
6.2.2.1.1 Need for high levels of expertise and growing drug development activities are driving the demand for contract manufacturing 65
TABLE 9 PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2018–2025 (USD MILLION) 66
6.2.2.2 Tablet manufacturing services 66
6.2.2.2.1 Shifting manufacturing requirements and the need to streamline production processes are driving market growth 66
TABLE 10 TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 67
6.2.2.3 Capsule manufacturing services 67
6.2.2.3.1 Growth in demand for capsule formulations has ensured growth opportunities for service providers 67
TABLE 11 CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 68
6.2.2.4 Oral liquid manufacturing services 69
6.2.2.4.1 Complexities involved in oral liquid manufacturing have prompted companies to opt for outsourcing 69
TABLE 12 ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 69
6.2.2.5 Semi-solid manufacturing services 70
6.2.2.5.1 Demand for specific manufacturing facilities to boost the outsourcing of semi-solids 70
TABLE 13 SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 70
6.2.2.6 Other formulations manufacturing services 71
TABLE 14 OTHER FORMULATIONS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 72
6.3 DRUG DEVELOPMENT SERVICES 72
6.3.1 DRUG SUBSTANCE COMPLEXITY AND HIGH COSTS HAVE SUPPORTED THE OUTSOURCING OF DRUG DEVELOPMENT 72
TABLE 15 DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 73
6.4 BIOLOGICS MANUFACTURING SERVICES 74
TABLE 16 BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 74
TABLE 17 BIOLOGICS MANUFACTURING SERVICES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 75
6.4.1 BIOLOGICS API MANUFACTURING SERVICES 75
6.4.1.1 Market for biologics API manufacturing is still in the nascent phase 75
TABLE 18 BIOLOGICS API MANUFACTURING SERVICES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 76
6.4.2 BIOLOGICS FDF MANUFACTURING SERVICES 76
6.4.2.1 Increasing R&D costs and process complexity have prompted the shift toward contract manufacturing 76
TABLE 19 BIOLOGICS FDF MANUFACTURING SERVICES MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 77

7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER 78
7.1 INTRODUCTION 79
TABLE 20 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION) 79
7.2 BIG PHARMACEUTICAL COMPANIES 80
7.2.1 EMERGENCE OF NEW MEDICINES AND THERAPIES TO CONTRIBUTE TO THE GROWTH OF THIS MARKET 80
TABLE 21 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY,
2018–2025 (USD MILLION) 81
7.3 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES 81
7.3.1 GROWING DEVELOPMENT OF BIOLOGIC DRUGS AND HIGH PRICING PRESSURE TO BOOST MARKET GROWTH 81
TABLE 22 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES,
BY COUNTRY, 2018–2025 (USD MILLION) 82
7.4 GENERIC PHARMACEUTICAL COMPANIES 83
7.4.1 GROWING DEMAND FOR GENERICS TO SUPPORT MARKET GROWTH 83
TABLE 23 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY,
2018–2025 (USD MILLION) 83
7.5 OTHER END USERS 84
TABLE 24 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2018–2025 (USD MILLION) 85
8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION 86
8.1 INTRODUCTION 87
FIGURE 21 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHICAL SNAPSHOT 87
TABLE 25 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION, 2018–2025 (USD MILLION) 88
8.2 EUROPE 88
FIGURE 22 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT 89
TABLE 26 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 90
TABLE 27 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION) 90
TABLE 28 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 90
TABLE 29 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 91
TABLE 30 EUROPE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION) 91
TABLE 31 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION) 91
8.2.1 GERMANY 92
8.2.1.1 High healthcare expenditure and increased pharmaceutical production to support market growth 92
TABLE 32 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION) 92
TABLE 33 GERMANY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 93
TABLE 34 GERMANY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 93
TABLE 35 GERMANY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 93
TABLE 36 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION) 94
8.2.2 ITALY 94
8.2.2.1 Increasing focus on clinical research and the growing popularity of branded drugs are driving the demand for contract development and manufacturing 94
TABLE 37 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION) 95
TABLE 38 ITALY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 95
TABLE 39 ITALY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 95
TABLE 40 ITALY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION) 96
TABLE 41 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION) 96
8.2.3 FRANCE 96
8.2.3.1 Presence of leading pharmaceutical companies to support market growth in France 96
TABLE 42 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION) 97
TABLE 43 FRANCE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 97
TABLE 44 FRANCE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 97
TABLE 45 FRANCE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION) 98
TABLE 46 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION) 98
8.2.4 UK 98
8.2.4.1 Growth in the generics market and the rising cost of manufacturing parenteral formulations are driving market growth 98
TABLE 47 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION) 99
TABLE 48 UK: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 99
TABLE 49 UK: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 99
TABLE 50 UK: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION) 100
TABLE 51 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION) 100
8.2.5 SWITZERLAND 100
8.2.5.1 Large volume of pharmaceutical production and growing scope for generics to provide growth opportunities 100
TABLE 52 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION) 101
TABLE 53 SWITZERLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 101
TABLE 54 SWITZERLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 101
TABLE 55 SWITZERLAND: BIOLOGICS MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 102
TABLE 56 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION) 102
8.2.6 SPAIN 102
8.2.6.1 Increase in biologics production to support market growth 102
TABLE 57 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION) 103
TABLE 58 SPAIN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 103
TABLE 59 SPAIN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 103
TABLE 60 SPAIN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION) 104
TABLE 61 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION) 104
8.2.7 REST OF EUROPE 104
TABLE 62 ROE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION) 105
TABLE 63 ROE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 105
TABLE 64 ROE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 105
TABLE 65 ROE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION) 106
TABLE 66 ROE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION) 106
8.3 NORTH AMERICA 106
TABLE 67 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 107
TABLE 68 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION) 107
TABLE 69 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 107
TABLE 70 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 108
TABLE 71 NORTH AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 108
TABLE 72 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION) 108
8.3.1 US 109
8.3.1.1 The US dominates the North American pharmaceutical contract development and manufacturing market 109
TABLE 73 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION) 109
TABLE 74 US: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 110
TABLE 75 US: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 110
TABLE 76 US: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION) 110
TABLE 77 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION) 111
8.3.2 CANADA 111
8.3.2.1 Growth of the emerging markets and slowdown in new product approvals will hamper the market growth 111
TABLE 78 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION) 111
TABLE 79 CANADA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 112
TABLE 80 CANADA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 112
TABLE 81 CANADA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION) 112
TABLE 82 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION) 113
8.4 ASIA PACIFIC 113
FIGURE 23 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT
AND MANUFACTURING MARKET SNAPSHOT 114
TABLE 83 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 115
TABLE 84 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION) 115
TABLE 85 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 115
TABLE 86 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 116
TABLE 87 ASIA PACIFIC: BIOLOGICS MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 116
TABLE 88 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION) 116
8.4.1 CHINA 117
8.4.1.1 Favorable government regulations are fueling market growth in China 117
TABLE 89 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION) 117
TABLE 90 CHINA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 118
TABLE 91 CHINA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 118
TABLE 92 CHINA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION) 118
TABLE 93 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION) 119
8.4.2 INDIA 119
8.4.2.1 Low manufacturing costs and a skilled workforce are factors attracting outsourcing and investment to India 119
TABLE 94 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION) 120
TABLE 95 INDIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 120
TABLE 96 INDIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 120
TABLE 97 INDIA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION) 121
TABLE 98 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION) 121
8.4.3 SOUTH KOREA 121
8.4.3.1 Government investments are a key contributor to market growth in South Korea 121
TABLE 99 SOUTH KOREA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION) 122
TABLE 100 SOUTH KOREA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 122
TABLE 101 SOUTH KOREA: BIOLOGICS MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 122
8.4.4 JAPAN 123
8.4.4.1 Growing generics demand and government initiatives to drive the demand for contract manufacturing of drugs 123
TABLE 102 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION) 123
TABLE 103 JAPAN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 124
TABLE 104 JAPAN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 124
TABLE 105 JAPAN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION) 124
TABLE 106 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION) 125
8.4.5 REST OF ASIA PACIFIC 125
TABLE 107 ROAPAC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION) 126
TABLE 108 ROAPAC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 126
TABLE 109 ROAPAC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 126
TABLE 110 ROAPAC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE,
2018–2025 (USD MILLION) 127
TABLE 111 ROAPAC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION) 127
8.5 LATIN AMERICA 127
8.5.1 FAVORABLE COST STRUCTURE AND GOVERNMENT INVESTMENTS TO DRIVE PHARMACEUTICAL PRODUCTION IN LATAM 127
TABLE 112 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION) 128
TABLE 113 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 128
TABLE 114 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 129
TABLE 115 LATIN AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET,
BY TYPE, 2018–2025 (USD MILLION) 129
TABLE 116 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018–2025 (USD MILLION) 129
8.6 MIDDLE EAST & AFRICA 130
8.6.1 GOVERNMENT SUPPORT TO BOOST LOCAL PRODUCTION IS EXPECTED TO OFFER GROWTH OPPORTUNITIES FOR CONTRACT MANUFACTURERS IN THE REGION 130
TABLE 117 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018–2025 (USD MILLION) 130
TABLE 118 MIDDLE EAST & AFRICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 131
TABLE 119 MIDDLE EAST & AFRICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018–2025 (USD MILLION) 131
9 COMPETITIVE LANDSCAPE 132
9.1 OVERVIEW 132
9.2 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 132
9.3 MARKET SHARE ANALYSIS 133
FIGURE 25 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET RANK, BY KEY PLAYER, 2019 134
TABLE 120 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEGREE OF COMPETITION 134
9.4 COMPETITIVE LEADERSHIP MAPPING 135
9.4.1 STARS 136
9.4.2 EMERGING LEADERS 136
9.4.3 PERVASIVE PLAYERS 136
9.4.4 PARTICIPANTS 136
FIGURE 26 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: COMPANY EVALUATION QUADRANT (2019) 137
9.5 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: START-UP/SME EVALUATION MATRIX, 2019 138
9.5.1 PROGRESSIVE COMPANIES 138
9.5.2 STARTING BLOCKS 138
9.5.3 RESPONSIVE COMPANIES 138
9.5.4 DYNAMIC COMPANIES 138
FIGURE 27 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: STARTUP/SME EVALUATION MATRIX, 2019 139
9.6 COMPANY SERVICE FOOTPRINT 140
TABLE 121 SERVICE PORTFOLIO ANALYSIS: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 140
9.7 COMPANY GEOGRAPHIC FOOTPRINT OF MAJOR PLAYERS IN THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 141
TABLE 122 GEOGRAPHIC REVENUE MIX: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET (2019) 141
9.8 COMPETITIVE SCENARIO 142
TABLE 123 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: SERVICE LAUNCHES, MAY 2019–OCTOBER 2020 143
TABLE 124 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEALS, MARCH 2019–JANUARY 2021 143
TABLE 125 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: OTHERS, MAY 2019–NOVEMBER 2020 144
10 COMPANY PROFILES 145
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
10.1 MAJOR PLAYERS 145
10.1.1 LONZA GROUP 145
TABLE 126 LONZA GROUP: BUSINESS OVERVIEW 145
FIGURE 28 LONZA GROUP: COMPANY SNAPSHOT (2020) 146
TABLE 127 LONZA GROUP: SERVICES OFFERED 146
10.1.2 THERMO FISHER SCIENTIFIC INC. 150
TABLE 128 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW 150
FIGURE 29 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2019) 151
TABLE 129 THERMO FISHER SCIENTIFIC: SERVICES OFFERED 151
10.1.3 CATALENT 154
TABLE 130 CATALENT: BUSINESS OVERVIEW 154
FIGURE 30 CATALENT: COMPANY SNAPSHOT (2020) 154
TABLE 131 CATALENT: SERVICES OFFERED 155
10.1.4 RECIPHARM AB 159
TABLE 132 RECIPHARM AB: BUSINESS OVERVIEW 159
FIGURE 31 RECIPHARM AB: COMPANY SNAPSHOT (2019) 159
TABLE 133 RECIPHARM AB: SERVICES OFFERED 160
10.1.5 ABBVIE 163
TABLE 134 ABBVIE: BUSINESS OVERVIEW 163
FIGURE 32 ABBVIE: COMPANY SNAPSHOT (2019) 163
TABLE 135 ABBVIE: SERVICES OFFERED 164
10.1.6 SIEGFRIED HOLDING AG 165
TABLE 136 SIEGFRIED HOLDING AG: BUSINESS OVERVIEW 165
FIGURE 33 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2019) 165
TABLE 137 SIEGFRIED HOLDING AG: SERVICES OFFERED 166
10.1.7 EVONIK INDUSTRIES 167
TABLE 138 EVONIK INDUSTRIES: BUSINESS OVERVIEW 167
FIGURE 34 EVONIK INDUSTRIES: COMPANY SNAPSHOT (2019) 167
TABLE 139 EVONIK INDUSTRIES: SERVICES OFFERED 168
10.1.8 BOEHRINGER INGELHEIM 169
TABLE 140 BOEHRINGER INGELHEIM: BUSINESS OVERVIEW 169
FIGURE 35 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2019) 170
TABLE 141 BOEHRINGER INGELHEIM: SERVICES OFFERED 170
10.1.9 PIRAMAL PHARMA SOLUTIONS 172
TABLE 142 PIRAMAL PHARMA SOLUTIONS: BUSINESS OVERVIEW 172
FIGURE 36 PIRAMAL PHARMA SOLUTIONS: COMPANY SNAPSHOT (2019) 172
TABLE 143 PIRAMAL PHARMA SOLUTIONS: SERVICES OFFERED 173
10.1.10 SAMSUNG BIOLOGICS 174
TABLE 144 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW 174
FIGURE 37 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2019) 174
TABLE 145 SAMSUNG BIOLOGICS: SERVICES OFFERED 175
10.1.11 WUXI APPTEC (WUXI STA) 177
TABLE 146 WUXI APPTEC: BUSINESS OVERVIEW 177
FIGURE 38 WUXI APPTEC: COMPANY SNAPSHOT (2019) 177
TABLE 147 WUXI APPTEC: SERVICES OFFERED 178
10.1.12 FUJIFILM HEALTHCARE 179
TABLE 148 FUJIFILM HEALTHCARE: BUSINESS OVERVIEW 179
FIGURE 39 FUJIFILM HEALTHCARE: COMPANY SNAPSHOT (2019) 179
TABLE 149 FUJIFILM HEALTHCARE: SERVICES OFFERED 180
10.2 OTHER PLAYERS 181
10.2.1 VETTER PHARMA INTERNATIONAL 181
TABLE 150 VETTER PHARMA INTERNATIONAL: BUSINESS OVERVIEW 181
TABLE 151 VETTER PHARMA INTERNATIONAL: SERVICES OFFERED 181
10.2.2 FAMAR HEALTH CARE SERVICES 183
TABLE 152 FAMAR HEALTH CARE SERVICES: BUSINESS OVERVIEW 183
TABLE 153 FAMAR HEALTH CARE SERVICES: SERVICES OFFERED 183
10.2.3 AENOVA GROUP 185
TABLE 154 AENOVA GROUP: BUSINESS OVERVIEW 185
TABLE 155 AENOVA GROUP: SERVICES OFFERED 185
10.2.4 ALMAC GROUP 186
10.2.5 CAMBREX 186
10.2.6 CORDENPHARMA 187
10.2.7 BIOVECTRA 187
10.2.8 ALBANY MOLECULAR RESEARCH 188
*Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
11 APPENDIX 189
11.1 DISCUSSION GUIDE 189
11.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 193
11.3 AVAILABLE CUSTOMIZATIONS 195
11.4 RELATED REPORTS 195
11.5 AUTHOR DETAILS 196



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の医薬品受託開発・製造市場予測(~2025年):医薬品別(生物製剤、医薬品有効成分)錠剤別(非経口、経口液剤、半固形物)、エンドユーザー別(大型医薬品、小型医薬品、ジェネリック医薬品、CRO)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆